 Scaling The Peaks Biotech Stocks Hitting 52-week Highs Aug. 4 ABIOMED, Inc. NASDAQ: ABMD FDA approved the emergency use of Abiomeds Impella heart pump in combination with an oxygen machine to treat Covid-19 patients who suffer heart and lung failure Allovir Inc NASDAQ: ALVR IPOed Thursday Alterity Therapeutics Ltd NASDAQ: ATHE announced positive preclinical data for its lead drug in Multiple System Atrophy ALX Oncology Holdings Inc NASDAQ: ALXO Cardiff Oncology Inc NASDAQ: CRDF Cocrystal Pharma Inc NASDAQ: COCP announced the publication of positive preclinical animal studies of coronavirus antiviral compounds in a medical journal Dr.Reddys Laboratories Ltd NYSE: RDY Fulgent Genetics Inc NASDAQ: FLGT Hologic, Inc. NASDAQ: HOLX Inari Medical Inc NASDAQ: NARI Inozyme Pharma Inc NASDAQ: INZY Quidel Corporation NASDAQ: QDEL Renalytix AI PLC NASDAQ: RNLX Sorrento Therapeutics Inc NASDAQ: SRNE Trevena Inc NASDAQ: TRVN Twist Bioscience Corp NASDAQ: TWST Varian Medical Systems, Inc. NYSE: VAR Zoetis Inc NYSE: ZTSDown In The Dumps Biotech Stocks Hitting 52-week Lows Aug. 4 Pandion Therapeutics Holdco LLC NASDAQ: PAND Verrica Pharmaceuticals Inc NASDAQ: VRCAStocks In Focus Novavax Announces Positive Phase 1 Data For Coronavirus Vaccine Novavax, Inc. NASDAQ: NVAX announced Phase 1 data from its Phase 12 randomized, observer-blinded, placebo-controlled trial of its COVID 19 vaccine NVX CoV2373 with and without Matrix M adjuvant, which showed the investigational vaccine was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera.Overall, the investigational vaccine was well-tolerated and had a reassuring safety profile.In after-hours trading, the stock rallied 12.62 to 177.Genfit Announces Publication of Data On Technology to Identify At-risk NASH Patients Genfit SA NASDAQ: GNFT said pivotal data describing the derivation and validation of NIS4 has been accepted for publication by The Lancet Gastroenterology and Hepatology. NIS4 is GENFITs non-invasive, blood-based diagnostic technology to identify patients with non-alcoholic steatohepatitis and significant to advanced fibrosis, also referred to as at-risk NASH in the published study.The complexity of underlying chronic liver diseases, such as NASH, is that these conditions often do not present with obvious symptoms until the disease is in very advanced stages.Hence, we believe non-invasive testing will continue to gain importance within healthcare systems given the capability to identify those who may require more aggressive medical intervention with a simple blood draw while maintaining high diagnostic accuracy, said Suneil Hosmane, Head of Global Diagnostics at GENFIT.In pre-market trading, the stock was gaining 5.71 to 5.55.Roche Gets FDA Authorization For Quantitative Test to Detect Epstein-Barr Virus Roche Holdings AG Basel ADR Common Stock OTC: RHHBY said the FDA has authorized the cobas EBV test, the first quantitative in vitro diagnostic test for Epstein-Barr virus DNA in the United States.This authorization gives healthcare professionals a key tool in monitoring transplant patients at risk for complications from infections or reactivations of EBV, by providing the ability to run a large number of patient tests for this virus in a short period of time, the company said.Aerpio Awarded 5.1M In Government Funding For A Mid-stage Study of COVID-19 Treatment Aerpio Pharmaceuticals Inc NASDAQ: ARPO announced an agreement with the U.S. government to evaluate its razuprotafib in a new investigational trial for the prevention and treatment of Acute Respiratory Distress Syndrome, or ARDS, in adult patients with moderate to severe COVID-19.The Medical Technology Enterprise Consortium, on behalf of the government, will provide up to 5.1 million in funding toward the clinical trial, while Aerpio will support the trial with a spending of 2.8 million.View more earnings on IBBThe partnership between Aerpio and MTEC will provide resources to support a second COVID-19 Phase 2 clinical trial, Aerpio said.The stock was jumping 44.70 to 1.91 in pre-market trading.BioNTech, Partner Fosun Begin Phase 1 Study of Coronavirus Vaccine Candidate In China BioNTech SE - ADR NASDAQ: BNTX and Fosun Pharma announced the first 72 participants have been dosed with BNT162b1 in a Phase 1 study in China following IND approval by the Chinese regulatory authority, National Medical Products Administration. The companies are jointly developing the COVID-19 vaccine candidate in China.The Phase 1 study, according to the companies, will evaluate safety and immunogenicity in Chinese participants to support potential regulatory approval in China.Earnings Fulgent Genetics second-quarter revenues jumped 105 year-over-year to 17.3 million, and the non-GAAP net income increased from 6 cents per share to 17 cents per share. The results were well ahead of consensus estimates.In after-hours trading, the stock jumped 16.20 to 34.50.Rigel Pharmaceuticals, Inc.s NASDAQ: RIGL second-quarter net loss per share narrowed from 12 cents in 2019 to 10 cents in 2020. Analysts, on average, had estimated a loss of 13 cents per share. Revenues increased year-over-year from 10.41 million to 16.02 million.The stock advanced 12.20 to 2.76.Vapotherm Inc NYSE: VAPO said its second-quarter revenues climbed 193.3 to 35.2 million. The loss per share narrowed from 76 cent in 2019 to 35 cents in 2020, while analysts expected a loss of 39 cents per share.For the third quarter, the company expects revenues of 24 million to 28 million, above the 18.65 million consensus estimate.The stock was plunging 28.44 to 37.75.On The Radar Earnings Constellation Pharmaceuticals Inc NASDAQ: CNST before the market open Vericel Corp NASDAQ: VCEL before the market open Eyepoint Pharmaceuticals Inc NASDAQ: EYPT before the market open PPD Inc NASDAQ: PPD before the market open Horizon Therapeutics PLC NASDAQ: HZNP before the market open Moderna Inc NASDAQ: MRNA before the market open Ionis Pharmaceuticals Inc NASDAQ: IONS before the market open Regeneron Pharmaceuticals Inc NASDAQ: REGN before the market open Harvard Bioscience, Inc. NASDAQ: HBIO before the market open IVERIC bio Inc NASDAQ: ISEE before the market open Brainstorm Cell Therapeutics Inc NASDAQ: BCLI before the market open BioDelivery Sciences International, Inc. NASDAQ: BDSI before the market open Allogene Therapeutics Inc NASDAQ: ALLO before the market open Arena Pharmaceuticals, Inc. NASDAQ: ARNA after the close ADMA Biologics Inc NASDAQ: ADMA after the close ACADIA Pharmaceuticals Inc. NASDAQ: ACAD after the close AxoGen, Inc Common Stock NASDAQ: AXGN after the close Arrowhead Pharmaceuticals Inc NASDAQ: ARWR after the close Global Blood Therapeutics Inc NASDAQ: GBT after the close Transenterix Inc NYSE: TRXC after the close Kindred Biosciences Inc NASDAQ: KIN after the close ResMed Inc. NYSE: RMD after the close Silk Road Medical Inc NASDAQ: SILK after the close Tricida Inc NASDAQ: TCDA after the close SurModics, Inc. NASDAQ: SRDX after the close Varian Medical Systems, Inc. NYSE: VAR after the close Immunomedics, Inc. NASDAQ: IMMU after the close PTC Therapeutics, Inc. NASDAQ: PTCT after the close Sangamo Therapeutics Inc NASDAQ: SGMO after the close TRACON Pharmaceuticals Inc NASDAQ: TCON after the close Lyra Therapeutics Inc NASDAQ: LYRA after the close Miragen Therapeutics Inc NASDAQ: MGEN after the close Zogenix, Inc. NASDAQ: ZGNX after the close Sarepta Therapeutics Inc NASDAQ: SRPT after the close Natera Inc NASDAQ: NTRA after the close OraSure Technologies, Inc. NASDAQ: OSUR after the close Orthopediatrics Corp NASDAQ: KIDS after the close G1 Therapeutics Inc NASDAQ: GTHX after the close Globus Medical Inc NYSE: GMED after the close TransMedics Group Inc NASDAQ: TMDX after the close Nevro Corp NYSE: NVRO after the close Collegium Pharmaceutical Inc NASDAQ: COLL after the close Endo International PLC NASDAQ: ENDP after the closeSee more from Benzinga The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings Attention Biotech Investors: Mark Your Calendar For August PDUFA DatesC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 